National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 16406-16407 [2017-06551]
Download as PDF
16406
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
of the contemplated Exclusive Patent
License. Comments and objections to
this notice submitted will not be made
available for public inspection and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 21, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2017–06546 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-up
Exclusive Evaluation Option Patent
License: ‘‘The Development and Use of
Diazeniumdiolated and Hybrid
Diazeniumdiolated Compounds for the
Treatment of Ovarian Cancer in
Humans’’
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of a Start-up Exclusive Evaluation
Option License to practice the
inventions embodied in the Patents and
Patent Applications listed in the
Supplementary Information section of
this notice to Tar Meta Biosciences, Inc.
(‘‘TarMeta’’) located in King of Prussia,
PA, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 19, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Start-up Exclusive Evaluation Option
License should be directed to: Kathleen
Higinbotham, Senior Technology
Transfer Manager, NCI Technology
Transfer Center, Riverside 5, Suite 400,
8490 Progress Dr., Frederick, MD 21701,
Telephone: (301)-624–8775; Facsimile:
(301)-631–3027 Email: higinbok@
mail.nih.gov.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Intellectual Property
(1) E–025–2010/0 entitled ‘‘Nitric Oxidebased Cancer Therapeutic Agents For Lung
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
Cancers With Elevated Levels Of Reactive
Oxygen Species (ROS) And/or Low Levels Of
Antioxidant Defense/DNA Repair
Mechanisms.’’
(a) United States Provisional Patent
Application No. 61/261,175 filed November
13, 2009;
(b) PCT Application No. PCT/US2010/
056446 filed November 12, 2010;
(c) United States Patent Application No.
13/509,431 filed June 01, 2012, US Patent
9,205,091 issued December 08, 2015;
(d) Australian Patent Application No.
2010319398 filed May 09, 2012;
(e) Canadian Patent Application No.
2,780,633 filed May 10, 2012;
(f) European Patent Application No.
10778814.3 filed May 14, 2012;
(2) E–220–2011/0 entitled ‘‘Hybrid
Diazeniumdiolated Compounds,
Pharmaceutical Compositions, And Method
Of Treating Cancer.’’
(a) United States Provisional Patent
Application No. 61/549,862, filed October 21,
2011;
(b) PCT Application No. PCT/US2012/
060785 filed October 18, 2012;
(c) United States Patent Application No.
14/352,096 filed April 16, 2014, US Patent
9,168,266 issued October 27, 2015;
(d) Australian Patent Application No.
2012326105 filed April 14, 2014;
(e) Canadian Patent Application No.
2,852,682 filed April 14, 2014;
(f) European Patent Application No.
12841601.3 filed April 14, 2014, European
Patent 2768824 issued December 07, 2016;
(i) German Patent 602012026435.7 issued
December 07, 2016;
(ii) French Patent 2768824 issued
December 07, 2016; and
(iii) UK Patent 2768824 issued December
07, 2016.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to ‘‘The
development and use of
diazeniumdiolated and hybrid
diazeniumdiolated compounds for the
treatment of ovarian cancer in humans.’’
The present inventions describe the
use of diazeniumdiolate-based nitric
oxide (NO)-releasing compounds
wherein the cancer cell has an elevated
level of reactive oxygen species (ROS),
as well as the use of hybrid prodrug
molecules that combine a
diazeniumdiolated compound and a
poly(ADP-ribose) polymerase (PARP)
inhibitor in cancer cells to produce
synergistic effects, whether alone or as
an adjuvant for other therapies. The
hybrid prodrug is expected to enhance
cytotoxicity by creating DNA damage
with NO and preventing its repair with
the PARP inhibitor. The prodrug and
the hybrid are activated by glutathione
S-transferase and are predicted to be
effective in cancers with reactive oxygen
species (ROS), both of which are
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
elevated in many cancers. In addition,
the prodrug and hybrid may have
synergy with therapeutics (such as
proteasome inhibitor bortezomib and
doxorubicin) which act through
generation of ROS. Taken together, these
features suggest that the prodrug and
hybrid may have therapeutic
applications in cancer patients whose
tumors include high levels of ROS.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Start-up Exclusive
Evaluation Option License will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 21, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–06545 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Molecular Mechanisms of Ventilator-Induced
Lung Injury.
Date: April 27, 2017.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7206, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Shelley S Sehnert, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7206, Bethesda, MD 20892–7924, 301–435–
0303, ssehnert@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: March 29, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–06551 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Frederick National Laboratory Advisory
Committee to the National Cancer
Institute.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will also be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov/).
Name of Committee: Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
Date: May 8, 2017.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: Ongoing and new activities at the
Frederick National Laboratory for Cancer
Research.
Place: National Institutes of Health, 31
Center Drive, Building 31, Wing C; 6th Floor,
Conference Room 10, Bethesda, MD 20892.
Contact Person: Caron A. Lyman, Ph.D.,
Executive Secretary, National Cancer
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
Institute, National Institutes of Health, 9609
Medical Center Drive, Room 7W–126,
Bethesda, MD 20892, 240–276–6348,
lymanc@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/fac/fac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 29, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
16407
Date: May 2, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200C, 7201
Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Greg Bissonette, Ph.D.,
Scientific Review Officer, National Institute
on Aging, National Institutes of Health,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892,
301–402–1622, bissonettegb@mail.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel, Translational
Bioinformatics and Alzheimer’s Disease.
Date: May 18, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2W200C, 7201
Wisconsin Ave., Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Greg Bissonette, Ph.D.,
Scientific Review Officer, National Institute
on Aging, National Institutes of
Health,Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892,
301–402–1622, bissonettegb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: March 29, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–06552 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2017–06550 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
National Institutes of Health
[Docket No. USCG–2017–0203]
National Institute on Aging; Notice of
Closed Meetings
National Maritime Security Advisory
Committee
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentablematerial,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
AGENCY:
Name of Committee: National Institute on
Aging Special Emphasis Panel,
Developmental Programming and Aging.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
Coast Guard, Department of
Homeland Security.
ACTION: Notice of Federal Advisory
Committee Meeting.
The National Maritime
Security Advisory Committee will meet
in Norfolk, Virginia, to review and
discuss various issues relating to
national maritime security. All meetings
will be open to the public.
DATES: The Committee will meet on
Tuesday, April 25, 2017, from 12 Noon
to 4:30 p.m. and on Wednesday, April
26, 2017, from 8 a.m. to 12 Noon. This
meeting may close early if all business
is finished.
ADDRESSES: The meeting will be held in
the Port of Virginia Conference Room on
the 6th floor of the World Trade Center,
SUMMARY:
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16406-16407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06551]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
[[Page 16407]]
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Molecular Mechanisms of Ventilator-Induced
Lung Injury.
Date: April 27, 2017.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7206, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Shelley S Sehnert, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7206, Bethesda, MD
20892-7924, 301-435-0303, ssehnert@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: March 29, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-06551 Filed 4-3-17; 8:45 am]
BILLING CODE 4140-01-P